Doubling the dose of the antiviral drug Tamiflu, or oseltamivir, doesn't benefit patients with severe flu, a study in BMJ found. Researchers tracked 326 people with severe flu at 13 hospitals in Southeast Asia and found no differences in virus levels, death rates and other outcomes between patients who took a standard dose of oseltamivir and those who received a double dose.

Full Story:
HealthDay News

Related Summaries